Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 193 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard COVID-19 therapies Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding

NCT04478019
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

NCT04380961
View directory record Official record
Conditions
Critical Confirmed Coronavirus Disease (COVID)-19
Interventions
Sirukumab, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years to 84 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Long Beach, California • Newport Beach, California • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19

NCT04724720
View directory record Official record
Conditions
Covid-19
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Withdrawn Phase 2 Interventional

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

NCT03376854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Sars-CoV2
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of Care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19

NCT04331899
View directory record Official record
Conditions
COVID-19
Interventions
Peginterferon Lambda-1a, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients

NCT04497389
View directory record Official record
Conditions
SARS CoV-2
Interventions
Human Amniotic Fluid
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 5, 2026, 5:12 PM EDT
Terminated Phase 3 Interventional

Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy

NCT04361253
View directory record Official record
Conditions
COVID, Infectious Disease
Interventions
High-Titer COVID-19 Convalescent Plasma (HT-CCP), Standard Plasma (FFP)
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Months and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 5, 2026, 5:12 PM EDT
Terminated Phase 2 Interventional Results available

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

NCT04305457
View directory record Official record
Conditions
Coronavirus Infections, Pneumonia, Viral, Acute Respiratory Distress Syndrome
Interventions
Nitric Oxide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Shreveport, Louisiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Not applicable Interventional Results available

Building Family Caregiver Skills Using a Simulation-Based Intervention for Care of Cancer Patients

NCT04055948
View directory record Official record
Conditions
Cancer
Interventions
One-on-one support/educational sessions, Telephone booster contact
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

NCT04842747
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
VERU-111
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • Chula Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Not applicable Interventional

UNITE Study (UMN-SW) for COVID-19

NCT04854798
View directory record Official record
Conditions
Covid19, Cytokine Storm, Inflammation
Interventions
Splenic Ultrasound
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Burnsville, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 5, 2026, 5:12 PM EDT
Withdrawn Phase 1 Interventional

Sirolimus in COVID-19 Phase 1

NCT04371640
View directory record Official record
Conditions
SARS-CoV-2, Covid-19
Interventions
Sirolimus 1 MG/ML, Placebo
Drug
Lead sponsor
Walter K. Kraft
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 5, 2026, 5:12 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection

NCT06084351
View directory record Official record
Conditions
Covid19
Interventions
Convalescent Plasma, Standard of Care
Drug · Other
Lead sponsor
Larkin Community Hospital
Other
Eligibility
40 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 5, 2026, 5:12 PM EDT
Withdrawn Phase 2 Interventional

Trial to Promote Recovery From COVID-19 With Endocrine Therapy

NCT04374279
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Bicalutamide 150 Mg Oral Tablet
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 1 Interventional

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

NCT04439006
View directory record Official record
Conditions
Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Ibrutinib
Other · Drug
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 5, 2026, 5:12 PM EDT
Active, not recruiting Not applicable Interventional

Mobile Peer Support for OUD Recovery

NCT05405712
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Mobile Phone App
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Not applicable Interventional

Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19

NCT04547283
View directory record Official record
Conditions
Covid19, Respiratory Failure
Interventions
Usual Care, APPS
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Not applicable Interventional

Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE)

NCT04350723
View directory record Official record
Conditions
Corona Virus Infection, Covid19, COVID-19
Interventions
Awake Proning
Procedure
Lead sponsor
St. Joseph's Healthcare Hamilton
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 5, 2026, 5:12 PM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 5, 2026, 5:12 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 5, 2026, 5:12 PM EDT
Not listed Not applicable Interventional

Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms

NCT04418505
View directory record Official record
Conditions
COVID-19
Interventions
Vielight RX Plus
Device
Lead sponsor
Vielight Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tocilizumab on Patients With COVID-19

NCT04356937
View directory record Official record
Conditions
SARS-CoV 2
Interventions
Tocilizumab, Placebos
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 5, 2026, 5:12 PM EDT
Not listed Not applicable Interventional

UNITE Study (UCSD-SW) for COVID-19

NCT04803409
View directory record Official record
Conditions
Covid19
Interventions
Splenic Ultrasound
Device
Lead sponsor
Imanuel Lerman
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 5, 2026, 5:12 PM EDT
Terminated Phase 2 Interventional Results available

Antithrombin III in Infectious Disease Caused by COVID-19

NCT04899232
View directory record Official record
Conditions
Antithrombin III Deficiency, Covid19
Interventions
Antithrombin III
Drug
Lead sponsor
Enrique Ginzburg
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 5, 2026, 5:12 PM EDT